JOP20220180A1 - مُعدلات ليباز أُحادِيُّ الجلِيسِريد - Google Patents
مُعدلات ليباز أُحادِيُّ الجلِيسِريدInfo
- Publication number
- JOP20220180A1 JOP20220180A1 JOP/2022/0180A JOP20220180A JOP20220180A1 JO P20220180 A1 JOP20220180 A1 JO P20220180A1 JO P20220180 A JOP20220180 A JO P20220180A JO P20220180 A1 JOP20220180 A1 JO P20220180A1
- Authority
- JO
- Jordan
- Prior art keywords
- methods
- disorders
- modifiers
- monoglyceride lipase
- depression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062972484P | 2020-02-10 | 2020-02-10 | |
| PCT/EP2021/053062 WO2021160602A1 (en) | 2020-02-10 | 2021-02-09 | Monoacylglycerol lipase modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20220180A1 true JOP20220180A1 (ar) | 2023-01-30 |
Family
ID=74595268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2022/0180A JOP20220180A1 (ar) | 2020-02-10 | 2022-08-09 | مُعدلات ليباز أُحادِيُّ الجلِيسِريد |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11708359B2 (https=) |
| EP (1) | EP4103557B1 (https=) |
| JP (1) | JP7795466B2 (https=) |
| KR (1) | KR20220140581A (https=) |
| CN (1) | CN115066422B (https=) |
| AR (1) | AR121296A1 (https=) |
| AU (1) | AU2021220539A1 (https=) |
| BR (1) | BR112022015116A2 (https=) |
| CA (1) | CA3169988A1 (https=) |
| CL (1) | CL2022002136A1 (https=) |
| CO (1) | CO2022011275A2 (https=) |
| CR (1) | CR20220376A (https=) |
| DO (1) | DOP2022000162A (https=) |
| EC (1) | ECSP22062460A (https=) |
| IL (1) | IL295447A (https=) |
| JO (1) | JOP20220180A1 (https=) |
| MX (1) | MX2022009804A (https=) |
| PE (1) | PE20221576A1 (https=) |
| PH (1) | PH12022552019A1 (https=) |
| TW (1) | TW202140465A (https=) |
| UY (1) | UY39066A (https=) |
| WO (1) | WO2021160602A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202140465A (zh) * | 2020-02-10 | 2021-11-01 | 比利時商健生藥品公司 | 單醯基甘油脂酶調節劑 |
| CN115362151B (zh) | 2020-03-26 | 2025-02-11 | 詹森药业有限公司 | 作为单酰基甘油脂肪酶调节剂的芳基哌啶 |
| MX2022011903A (es) | 2020-03-26 | 2023-01-11 | Janssen Pharmaceutica Nv | Azaspirociclos como moduladores de monoacilglicerol lipasa. |
| WO2021191391A1 (en) | 2020-03-26 | 2021-09-30 | Janssen Pharmaceutica Nv | Aminocyclobutanes as monoacylglycerol lipase modulators |
| US12115154B2 (en) | 2020-12-16 | 2024-10-15 | Srx Cardio, Llc | Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) |
| CA3228446A1 (en) | 2021-08-09 | 2023-02-16 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators for use in autism spectrum disorders |
| CA3242372A1 (en) | 2021-12-29 | 2023-07-06 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2493637A1 (en) | 2002-07-25 | 2004-02-12 | Manuela Villa | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| EP2090576A1 (en) | 2008-02-01 | 2009-08-19 | Merz Pharma GmbH & Co.KGaA | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators |
| KR20140068243A (ko) * | 2011-09-30 | 2014-06-05 | 얀센 파마슈티카 엔.브이. | 대사 질환 및 관련 장애의 치료를 위한 모노아실글리세롤 리파제 억제제 |
| WO2017170830A1 (ja) | 2016-03-31 | 2017-10-05 | 武田薬品工業株式会社 | 複素環化合物 |
| EA036637B1 (ru) | 2016-03-31 | 2020-12-02 | Такеда Фармасьютикал Компани Лимитед | Гетероциклические спиросоединения, ингибирующие моноацилглицерин-липазу |
| GB201613163D0 (en) | 2016-07-29 | 2016-09-14 | Autifony Therapeutics Ltd | Novel compounds |
| MX2020007318A (es) * | 2017-09-29 | 2020-08-24 | Takeda Pharmaceuticals Co | Compuesto heterociclico. |
| CN112272670B (zh) | 2019-04-16 | 2023-12-12 | 上海翰森生物医药科技有限公司 | 含二并环类衍生物抑制剂、其制备方法和应用 |
| TW202140465A (zh) | 2020-02-10 | 2021-11-01 | 比利時商健生藥品公司 | 單醯基甘油脂酶調節劑 |
| CN115362151B (zh) | 2020-03-26 | 2025-02-11 | 詹森药业有限公司 | 作为单酰基甘油脂肪酶调节剂的芳基哌啶 |
| MX2022011903A (es) | 2020-03-26 | 2023-01-11 | Janssen Pharmaceutica Nv | Azaspirociclos como moduladores de monoacilglicerol lipasa. |
| WO2021191391A1 (en) | 2020-03-26 | 2021-09-30 | Janssen Pharmaceutica Nv | Aminocyclobutanes as monoacylglycerol lipase modulators |
-
2021
- 2021-02-09 TW TW110104960A patent/TW202140465A/zh unknown
- 2021-02-09 CA CA3169988A patent/CA3169988A1/en active Pending
- 2021-02-09 KR KR1020227031216A patent/KR20220140581A/ko not_active Withdrawn
- 2021-02-09 PE PE2022001698A patent/PE20221576A1/es unknown
- 2021-02-09 JP JP2022548400A patent/JP7795466B2/ja active Active
- 2021-02-09 CR CR20220376A patent/CR20220376A/es unknown
- 2021-02-09 UY UY0001039066A patent/UY39066A/es unknown
- 2021-02-09 US US17/171,559 patent/US11708359B2/en active Active
- 2021-02-09 MX MX2022009804A patent/MX2022009804A/es unknown
- 2021-02-09 CN CN202180013762.3A patent/CN115066422B/zh active Active
- 2021-02-09 AU AU2021220539A patent/AU2021220539A1/en active Pending
- 2021-02-09 EP EP21705124.2A patent/EP4103557B1/en active Active
- 2021-02-09 IL IL295447A patent/IL295447A/en unknown
- 2021-02-09 PH PH1/2022/552019A patent/PH12022552019A1/en unknown
- 2021-02-09 BR BR112022015116A patent/BR112022015116A2/pt unknown
- 2021-02-09 WO PCT/EP2021/053062 patent/WO2021160602A1/en not_active Ceased
- 2021-02-09 AR ARP210100333A patent/AR121296A1/es not_active Application Discontinuation
-
2022
- 2022-08-08 CL CL2022002136A patent/CL2022002136A1/es unknown
- 2022-08-09 EC ECSENADI202262460A patent/ECSP22062460A/es unknown
- 2022-08-09 JO JOP/2022/0180A patent/JOP20220180A1/ar unknown
- 2022-08-10 CO CONC2022/0011275A patent/CO2022011275A2/es unknown
- 2022-08-10 DO DO2022000162A patent/DOP2022000162A/es unknown
-
2023
- 2023-06-02 US US18/328,242 patent/US20230382902A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CR20220376A (es) | 2022-09-16 |
| MX2022009804A (es) | 2022-09-02 |
| CA3169988A1 (en) | 2021-08-19 |
| CN115066422B (zh) | 2024-11-22 |
| PH12022552019A1 (en) | 2023-11-29 |
| US11708359B2 (en) | 2023-07-25 |
| ECSP22062460A (es) | 2022-11-30 |
| US20230382902A1 (en) | 2023-11-30 |
| EP4103557C0 (en) | 2026-02-18 |
| JP2023512729A (ja) | 2023-03-28 |
| BR112022015116A2 (pt) | 2022-09-27 |
| AU2021220539A1 (en) | 2022-10-06 |
| CO2022011275A2 (es) | 2022-08-30 |
| DOP2022000162A (es) | 2022-10-31 |
| TW202140465A (zh) | 2021-11-01 |
| IL295447A (en) | 2022-10-01 |
| PE20221576A1 (es) | 2022-10-06 |
| JP7795466B2 (ja) | 2026-01-07 |
| EP4103557A1 (en) | 2022-12-21 |
| EP4103557B1 (en) | 2026-02-18 |
| CL2022002136A1 (es) | 2023-02-03 |
| KR20220140581A (ko) | 2022-10-18 |
| UY39066A (es) | 2021-08-31 |
| WO2021160602A1 (en) | 2021-08-19 |
| CN115066422A (zh) | 2022-09-16 |
| US20210253565A1 (en) | 2021-08-19 |
| AR121296A1 (es) | 2022-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20220180A1 (ar) | مُعدلات ليباز أُحادِيُّ الجلِيسِريد | |
| SA521421575B1 (ar) | مُعدلات ليباز أُحادِيُّ الجلِيسِريد | |
| MX2021003661A (es) | Moduladores de la monoacilglicerol lipasa. | |
| MX2022011904A (es) | Aminociclobutanos como moduladores de monoacilglicerol lipasa. | |
| MX2022011903A (es) | Azaspirociclos como moduladores de monoacilglicerol lipasa. | |
| MX2022011901A (es) | Arilo piperidinas como moduladores de monoacilglicerol lipasa. | |
| MX2023003240A (es) | Moduladores de monoacilglicerol lipasa de ciclobutilamida. | |
| MX2022011902A (es) | Moduladores de la monoacilglicerol lipasa. | |
| CO2025015814A2 (es) | Inhibidores de kras de 2-azabiciclo [2.2.1] heptano | |
| EA201100461A1 (ru) | Спиро-трициклические соединения как модуляторы бета-секретазы и способы их использования | |
| MX366855B (es) | Compuestos perfluorados de 5,6-dihidro-4h-1,3-oxazin-2-amina como inhibidores de beta-secretasa y metodos de uso. | |
| JP2012522731A (ja) | ピロロキノリンキノンのリチウム誘導体及びその製造方法 | |
| PE20210412A1 (es) | Moduladores de sting (estimulador de genes de interferon) a base de ciclopentano | |
| GEAP202416612A (en) | Tricyclic urea compounds as jak2 v617f inhibitors | |
| MX2024007220A (es) | Psicoplastogenos de pirrolidina fusionada y sus usos. | |
| TN2020000161A1 (en) | CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGIuR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | |
| MX394391B (es) | Derivados de tiazina y oxazina biciclicos como inhibidores de beta-secretasa y metodos de uso. | |
| MX2024010344A (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa | |
| MX2023002350A (es) | Composiciones y metodos para mejorar enfermedades y trastornos neurologicos. | |
| Hagerman et al. | Case series: deep brain stimulation in patients with FXTAS | |
| WO2023069425A3 (en) | Gene therapy for the treatment of wilson''s disease | |
| WO2024077043A3 (en) | Modifying early-stage parkinson's disease progression with deep brain stimulation | |
| MX2025007377A (es) | Inhibidores de jak2 | |
| EA201992628A1 (ru) | Ингибиторы bcl6, полученные из бензимидазолона | |
| MX2026002937A (es) | Nuevas fenilalquilaminas y su uso en el tratamiento de trastornos psiquiatricos |